tissue plasminogen activator

(redirected from Alteplase)
Also found in: Dictionary, Thesaurus, Medical.

tissue plasminogen activator

[¦tish·ü plaz‚min·ə·jən ′ak·tə‚vād·ər]
(medicine)
A proteolytic enzyme that can convert plasminogen to plasmin.
References in periodicals archive ?
Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion.
In our case, we decided to administer intravenous heparin plus alteplase as a systemic thrombolytic.
Japan Alteplase Clinical Trial (J-ACT) research results suggest that a low dose of tPA (0.6 mg/kg) intravenous thrombolytic therapy in the Japanese population can obtain similar clinical efficacy as the standard dose of National Institute of Neurological Disorders and Stroke (NINDS) and can reduce the risk of SICH (18).
second-generation devices) performed in addition to early alteplase treatment within 6 hours of AIS in suitable patients doubles the rate of angiographic revascularisation at 24 hours and functional independence at 3 months.
(3) Mr J was successfully treated with alteplase after reversal of dabigatran with idarucizumab.
Campbell, Ph.D., from the Melbourne Brain Centre in Australia, and colleagues randomized 202 patients with ischemic stroke who had occlusion of the internal carotid, basilar, or middle cerebral artery, and who were eligible for thrombectomy, to receive tenecteplase (101 patients) or alteplase (101 patients) within 4.5 hours after symptom onset.
For patients with blood pressure lower than 220/120 mm Hg who did not receive IV alteplase or thrombectomy, treatment of hypertension in the first 48-72 hours after an MS does not change the outcome.
Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial.
Bluhmki et al., "Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke," The New England Journal ofMedicine, vol.
Viana-Baptista, "Orolingual angiodema associated with alteplase treatment of acute stroke: A reappraisal," Journal of Stroke and Cerebrovascular Diseases, vol.
Although we infused the dose of alteplase over 2 hours as per the manufacturer's recommendation [30], others have recommended a more rapid infusion strategy (e.g., a 50 mg bolus injection of alteplase with an option for a repeat bolus 15 minutes later or an accelerated regimen of 0,6 mg alteplase/kg over 15 minutes) [31, 32].